

For Immediate Release
For Further Information Contact:
Therese Fergo at (301) 608-9292
Email: Therese@unither.com

UNITED THERAPEUTICS ANNOUNCES PRESENTATIONS OF LONG-TERM FOLLOW-UP DATA ON REMODULIN PATIENTS

Silver Spring, MD, May 9, 2001: United Therapeutics Corporation (Nasdaq: UTHR) today announced that clinical investigators have independently submitted data to upcoming medical conferences demonstrating that patients with pulmonary hypertension continued to improve their exercise capacity, as assessed by 6-minute walk distance, after long-term treatment with Remodulin.

Dr. Vallerie McLaughlin, of Rush Presbyterian-St. Lukes Medical Center, with other co-investigators have submitted an abstract to the Heart Failure Society of America (HFSA) for its 5th Annual Scientific Meeting to be held in Washington, DC in September 2001. The HFSA abstract was based on 50 patients and showed that patients with pulmonary hypertension increased their baseline walking distance by 40 meters on average after 12 months of Remodulin therapy. Dr. McLaughlin and colleagues have also submitted an abstract to the American Heart Association (AHA) 2001 Scientific Sessions to be held in Anaheim, California in November that summarizes United Therapeutics larger, multicenter experience confirming the continued improvement in exercise capacity in a larger sample of patients.

Another abstract summarizing an additional 52-patient subset will be reported by a separate team of investigators at the upcoming American Thoracic Society's 97th International Conference in May 2001 in San Francisco. In this study, patients considered to be responders to Remodulin therapy (defined as achieving walking distance improvements of greater than 10%) showed walking distance improvements of 98 meters on average after 18 months of Remodulin therapy.

"We are pleased to see that patients continue to improve with chronic Remodulin therapy, in this case for up to 18 months" said Roger Jeffs, Ph.D. President of United Therapeutics. "As with many vasoactive medications, there was a need for the dose of Remodulin to be increased over time, with approximately an 8-fold increase in Remodulin dose over 18 months. This increased dose of Remodulin was well-tolerated and these presentations support the findings from our pivotal and long-term trials that chronic Remodulin therapy provides meaningful benefit to patients with this life-threatening disease."

Pulmonary hypertension is a life-threatening condition of high blood pressure between the heart and lungs. Remodulin is a promising new medicine for this condition and is currently under active review by US and European regulatory authorities. Increase in

walking ability is the standard measure of effectiveness in assessing the potential of pulmonary hypertension drugs.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious disease with unique therapeutic products. United Therapeutics is a member of the Russell 3000 Index and is included in the iShares Nasdaq Biotechnology Index Fund (NBI).